𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial

✍ Scribed by C. F. McDonald; R. M. D. Zebaze; E. Seeman

Publisher
Springer-Verlag
Year
2006
Tongue
English
Weight
148 KB
Volume
17
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interferon-Ξ± does not improve outcome at
Interferon-Ξ± does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial
✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 161 KB πŸ‘ 1 views

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal

The effect of moderate-dose corticostero
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial
✍ Chung-E Tseng; Jill P. Buyon; Mimi Kim; H. Michael Belmont; Meggan Mackay; Betty πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

## Abstract ## Objective Serial measurements of anti–double‐stranded DNA (anti‐dsDNA) and complement are routine in the management of systemic lupus erythematosus (SLE), but their utility as biomarkers in preemptive treatment to prevent flares remains a subject of controversy. We hypothesized that